Bone Morphogenetic Protein-2 and Vascular Endothelial Growth Factor in Bone Tissue Regeneration: New Insight and Perspectives

Orthopaedic Surgery

Volumn 6, Issue 3, 2014, Pages 171-178

  Aryal, Rajendra ^a   Chen, Xiao Peng ^a   Fang, Cheng ^a   Hu, Yong Cheng ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Hospital   (China)

Author keywords

Bone morphogenetic protein 2; Bone tissue regeneration; Vascular endothelial growth factor

Indexed keywords

EID: 84999907717     PISSN: 17577853     EISSN: None     Source Type: Journal    
DOI: 10.1111/os.12112     Document Type: Review

References (96)

1. Reichert JC, Saifzadeh S, Wullschleger ME, et al. The challenge of establishing preclinical models for segmental bone defect research. Biomaterials, 2009, 30: 2149–2163.
2. Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury, 2005, 36: 1392–1404.
3. Moreno LA, Valtueña J, Pérez-López F, González-Gross M. Health effects related to low vitamin D concentrations: beyond bone metabolism. Ann Nutr Metab, 2011, 59: 22–27.
4. Amini AR, Laurencin CT, Nukavarapu SP. Bone tissue engineering: recent advances and challenges. Crit Rev Biomed Eng, 2012, 40: 363–408.
5. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface, 2011, 8: 153–170.
6. Goldberg VM, Stevenson S. Natural history of autografts and allografts. Clin Orthop Relat Res, 1987, 225: 7–16.
7. Chiapasco M, Casentini P, Zaniboni M. Bone augmentation procedures in implant dentistry. Int J Oral Maxillofac Implants, 2009, 24 (Suppl.): 237–259.
8. Mickiewicz P, Binkowski M, Bursig H, Wróbel Z. Preservation and sterilization methods of the meniscal allografts: literature review. Cell Tissue Bank, 2013, 2013: 1–11.
9. Nauth A, Ristevski B, Li R, Schemitsch EH. Growth factors and bone regeneration: how much bone can we expect? Injury, 2011, 42: 574–579.
10. Conway JD. Autograft and nonunions: morbidity with intramedullary bone graft versus iliac crest bone graft. Orthop Clin North Am, 2010, 41: 75–84.
11. Zellin G. Growth factors and bone regeneration. Implications of barrier membranes. Swed Dent J Suppl, 1998, 129: 7–65.
12. Park do J, Yoon C, Thomas N, et al. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Ann Surg Oncol, 2014, 21: 1130–1137.
13. Eap S, Ferrand A, Schiavi J, et al. Collagen implants equipped with “fish scale”-like nanoreservoirs of growth factors for bone regeneration. Nanomedicine (Lond), 2013, [Epub ahead of print]
14. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am, 2002, 84: 1032–1044.
15. Geuze RE, Theyse LF, Kempen DH, et al. A differential effect of bone morphogenetic protein-2 and vascular endothelial growth factor release timing on osteogenesis at ectopic and orthotopic sites in a large-animal model. Tissue Eng Part A, 2012, 18: 2052–2062.
16. Hernandez A, Reyes R, Sanchez E, Rodriguez-Evora M, Delgado A, Evora C. In vivo osteogenic response to different ratios of BMP-2 and VEGF released from a biodegradable porous system. J Biomed Mater Res A, 2012, 100: 2382–2391.
17. Gorskaya YF, Danilova TA, Mezentseva MV, et al. Effect of BMP-2 protein on the count and osteogenic properties of multipotent stromal cells and expression of cytokine genes in primary cultures of bone marrow and spleen cells from CBA mice immunized with bacterial antigens. Bull Exp Biol Med, 2013, 155: 650–654.
18. Winn SR, Uludag H, Hollinger JO. Carrier systems for bone morphogenetic proteins. Clin Orthop Relat Res, 1999, 367 (Suppl): S95–106.
19. Suárez-González D, Lee JS, Diggs A, et al. Controlled multiple growth factor delivery from bone tissue engineering scaffolds via designed affinity. Tissue Eng Part A, 2013, [Epub ahead of print].
20. Bae MS, Ohe JY, Lee JB, et al. Photo-cured hyaluronic acid-based hydrogels containing growth and differentiation factor 5 (GDF-5) for bone tissue regeneration. Bone, 2013, 59C: 189–198.
21. Sampath TK, Coughlin JE, Whetstone RM, et al. Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two members of the transforming growth factor-beta superfamily. J Biol Chem, 1990, 265: 13198–13205.
22. Jeon O, Rhie JW, Kwon IK, Kim JH, Kim BS, Lee SH. In vivo bone formation following transplantation of human adipose-derived stromal cells that are not differentiated osteogenically. Tissue Eng Part A, 2008, 14: 1285–1294.
23. Rivera JC, Strohbach CA, Wenke JC, Rathbone CR. Beyond osteogenesis: an in vitro comparison of the potentials of six bone morphogenetic proteins. Front Pharmacol, 2013, 4: 125.
24. Tirkkonen L, Haimi S, Huttunen S, et al. Osteogenic medium is superior to growth factors in differentiation of human adipose stem cells towards bone-forming cells in 3D culture. Eur Cell Mater, 2013, 25: 144–158.
25. Arosarena OA, Collins WL. Bone regeneration in the rat mandible with bone morphogenetic protein-2: a comparison of two carriers. Otolaryngol Head Neck Surg, 2005, 132: 592–597.
26. Chu TM, Warden SJ, Turner CH, Stewart RL. Segmental bone regeneration using a load-bearing biodegradable carrier of bone morphogenetic protein-2. Biomaterials, 2007, 28: 459–467.
27. Evans KN, Potter BK, Brown TS, Davis TA, Elster EA, Forsberg JA. Osteogenic gene expression correlates with development of heterotopic ossification in war wounds. Clin Orthop Relat Res, 2014, 472: 396–404.
28. Li H, Dai K, Tang T, Zhang X, Yan M, Lou J. Bone regeneration by implantation of adipose-derived stromal cells expressing BMP-2. Biochem Biophys Res Commun, 2007, 356: 836–842.
29. Knippenberg M, Helder MN, Zandieh DB, Wuisman PI, Klein-Nulend J. Osteogenesis versus chondrogenesis by BMP-2 and BMP-7 in adipose stem cells. Biochem Biophys Res Commun, 2006, 342: 902–908.
30. Hollinger JO, Schmitt JM, Buck DC, et al. Recombinant human bone morphogenetic protein-2 and collagen for bone regeneration. J Biomed Mater Res, 1998, 43: 356–364.
31. Keibl C, Fugl A, Zanoni G, et al. Human adipose derived stem cells reduce callus volume upon BMP-2 administration in bone regeneration. Injury, 2011, 42: 814–820.
32. Lin CY, Lin KJ, Kao CY, et al. The role of adipose-derived stem cells engineered with the persistently expressing hybrid baculovirus in the healing of massive bone defects. Biomaterials, 2011, 32: 6505–6514.
33. Brown KV, Li B, Guda T, Perrien DS, Guelcher SA, Wenke JC. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release. Tissue Eng Part A, 2011, 17: 1735–1746.
34. Song I, Kim BS, Kim CS, Im GI. Effects of BMP-2 and vitamin D3 on the osteogenic differentiation of adipose stem cells. Biochem Biophys Res Commun, 2011, 408: 126–131.
35. Liao X, Wu L, Fu M, et al. Chondrogenic phenotype differentiation of bone marrow mesenchymal stem cells induced by bone morphogenetic protein 2 under hypoxic microenvironment in vitro. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2012, 26: 743–748.
36. Kwon SH, Lee TJ, Park J, et al. Modulation of BMP-2-induced chondrogenic versus osteogenic differentiation of human mesenchymal stem cells by cell-specific extracellular matrices. Tissue Eng Part A, 2013, 19: 49–58.
37. Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. Ann Intern Med, 2013, 158: 877–889.
38. Fan J, Park H, Tan S, Lee M. Enhanced osteogenesis of adipose derived stem cells with Noggin suppression and delivery of BMP-2. PLoS ONE, 2013, 8: e72474.
39. Chou YF, Zuk PA, Chang TL, Benhaim P, Wu BM. Adipose-derived stem cells and BMP2: part 1. BMP2-treated adipose-derived stem cells do not improve repair of segmental femoral defects. Connect Tissue Res, 2011, 52: 109–118.
40. Li Q, Wang Z. Influence of mesenchymal stem cells with endothelial progenitor cells in co-culture on osteogenesis and angiogenesis: an in vitro study. Arch Med Res, 2013, 44: 504–513.
41. Detsch R, Stoor P, Grünewald A, Roether JA, Lindfors NC, Boccaccini AR. Increase in VEGF secretion from human fibroblast cells by bioactive glass S53P4 to stimulate angiogenesis in bone. J Biomed Mater Res A, 2014, doi: 10.1002/jbm.a.35069. [Epub ahead of print]
42. Hoffmann BR, Wagner JR, Prisco AR, Janiak A, Greene AS. Vascular endothelial growth factor-A signaling in bone marrow-derived endothelial progenitor cells exposed to hypoxic stress. Physiol Genomics, 2013, 45: 1021–1034.
43. Dimitriou R, Jones E, McGonagle D, Giannoudis PV. Bone regeneration: current concepts and future directions. BMC Med, 2011, 9: 66.
44. Willems WF, Kremer T, Friedrich P, Bishop AT. Surgical revascularization induces angiogenesis in orthotopic bone allograft. Clin Orthop Relat Res, 2012, 470: 2496–2502.
45. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes, 1999, 48: 2229–2239.
46. Maes C. Role and regulation of vascularization processes in endochondral bones. Calcif Tissue Int, 2013, 92: 307–323.
47. Fischer LJ, McIlhenny S, Tulenko T, et al. Endothelial differentiation of adipose-derived stem cells: effects of endothelial cell growth supplement and shear force. J Surg Res, 2009, 152: 157–166.
48. Froehlich H, Gulati R, Boilson B, et al. Carotid repair using autologous adipose-derived endothelial cells. Stroke, 2009, 40: 1886–1891.
49. Traktuev DO, Prater DN, Merfeld-Clauss S, et al. Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. Circ Res, 2009, 104: 1410–1420.
50. Dirckx N, Van Hul M, Maes C. Osteoblast recruitment to sites of bone formation in skeletal development, homeostasis, and regeneration. Birth Defects Res C Embryo Today, 2013, 99: 170–191.
51. Niklas A, Proff P, Gosau M, Römer P. The role of hypoxia in orthodontic tooth movement. Int J Dent, 2013, 2013: 841840.
52. Liu B, Li X, Liang G, Liu X. VEGF expression in mesenchymal stem cells promotes bone formation of tissue-engineered bones. Mol Med Rep, 2011, 4: 1121–1126.
53. Wernike E, Montjovent MO, Liu Y, et al. VEGF incorporated into calcium phosphate ceramics promotes vascularisation and bone formation in vivo. Eur Cell Mater, 2010, 19: 30–40.
54. Kleinheinz J, Stratmann U, Joos U, Wiesmann HP. VEGF-activated angiogenesis during bone regeneration. J Oral Maxillofac Surg, 2005, 63: 1310–1316.
55. Kaigler D, Silva EA, Mooney DJ. Guided bone regeneration using injectable vascular endothelial growth factor delivery gel. J Periodontol, 2013, 84: 230–238.
56. Balseiro S, Nottmeier EW. Vertebral osteolysis originating from subchondral cyst end plate defects in transforaminal lumbar interbody fusion using rhBMP-2. Report of two cases. Spine J, 2010, 10: e6–10.
57. Carragee EJ, Chu G, Rohatgi R, et al. Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am, 2013, 95: 1537–1545.
58. Dimar JN, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am, 2009, 91: 1377–1386.
59. Helmrich U, Di Maggio N, Guven S, et al. Osteogenic graft vascularization and bone resorption by VEGF-expressing human mesenchymal progenitors. Biomaterials, 2013, 34: 5025–5035.
60. Xiao C, Zhou H, Liu G, et al. Bone marrow stromal cells with a combined expression of BMP-2 and VEGF-165 enhanced bone regeneration. Biomed Mater, 2011, 6: 15013.
61. Furumatsu T, Shen ZN, Kawai A, et al. Vascular endothelial growth factor principally acts as the main angiogenic factor in the early stage of human osteoblastogenesis. J Biochem, 2003, 133: 633–639.
62. Deckers MM, van Bezooijen RL, van der Horst G, et al. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology, 2002, 143: 1545–1553.
63. Street J, Bao M, DeGuzman L, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A, 2002, 99: 9656–9661.
64. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med, 1999, 5: 623–628.
65. Deckers MM, Karperien M, van der Bent C, Yamashita T, Papapoulos SE, Lowik CW. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology, 2000, 141: 1667–1674.
66. Pufe T, Wildemann B, Petersen W, Mentlein R, Raschke M, Schmidmaier G. Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing: a study in the rat. Cell Tissue Res, 2002, 309: 387–392.
67. Cui Q, Dighe AS, Irvine JJ. Combined angiogenic and osteogenic factor delivery for bone regenerative engineering. Curr Pharm Des, 2013, 19: 3374–3383.
68. Glowacki J, Zhou S, Mizuno S. Mechanisms of osteoinduction/chondroinduction by demineralized bone. J Craniofac Surg, 2009, 20 (Suppl. 1): 634–638.
69. Peng H, Usas A, Hannallah D, Olshanski A, Cooper GM, Huard J. Noggin improves bone healing elicited by muscle stem cells expressing inducible BMP4. Mol Ther, 2005, 12: 239–246.
70. Kanczler JM, Oreffo RO. Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater, 2008, 15: 100–114.
71. Patel ZS, Young S, Tabata Y, Jansen JA, Wong ME, Mikos AG. Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model. Bone, 2008, 43: 931–940.
72. Ehnert S, Zhao J, Pscherer S, et al. Transforming growth factor beta1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy? BMC Med, 2012, 10: 101.
73. Young S, Patel ZS, Kretlow JD, et al. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model. Tissue Eng Part A, 2009, 15: 2347–2362.
74. El BR, Zaky SH, Muraglia A, et al. A platelet-rich plasma-based membrane as a periosteal substitute with enhanced osteogenic and angiogenic properties: a new concept for bone repair. Tissue Eng Part A, 2013, 19: 152–165.
75. Samee M, Kasugai S, Kondo H, Ohya K, Shimokawa H, Kuroda S. Bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) transfection to human periosteal cells enhances osteoblast differentiation and bone formation. J Pharmacol Sci, 2008, 108: 18–31.
76. Dai J, Li Y, Zhou H, Chen J, Chen M, Xiao Z. Genistein promotion of osteogenic differentiation through BMP2/SMAD5/RUNX2 signaling. Int J Biol Sci, 2013, 9: 1089–1098.
77. Zheng Y, Feng Z, You C, et al. In vitro evaluation of Panax notoginseng Rg1 released from collagen/chitosan-gelatin microsphere scaffolds for angiogenesis. Biomed Eng Online, 2013, 12: 134.
78. Kempen DH, Lu L, Heijink A, et al. Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials, 2009, 30: 2816–2825.
79. Kimelman BN, Kallai I, Lieberman JR, Schwarz EM, Pelled G, Gazit D. Gene therapy approaches to regenerating bone. Adv Drug Deliv Rev, 2012, 64: 1320–1330.
80. Pensak MJ, Lieberman JR. Gene therapy for bone regeneration. Curr Pharm Des, 2013, 19: 3466–3473.
81. Liu F, Porter RM, Wells J, Glatt V, Pilapil C, Evans CH. Evaluation of BMP-2 gene-activated muscle grafts for cranial defect repair. J Orthop Res, 2012, 30: 1095–1102.
82. Moutsatsos IK, Turgeman G, Zhou S, et al. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol Ther, 2001, 3: 449–461.
83. Gafni Y, Turgeman G, Liebergal M, Pelled G, Gazit Z, Gazit D. Stem cells as vehicles for orthopedic gene therapy. Gene Ther, 2004, 11: 417–426.
84. Muthukuru M, Sun J. Doxycycline counteracts bone morphogenic protein 2-induced osteogenic mediators. J Periodontol, 2013, 84: 656–665.
85. Nakai K. [Controlling signal transduction with synthetic ligands]. Tanpakushitsu Kakusan Koso, 2007, 52: 1794–1795.
86. Koh JT, Ge C, Zhao M, et al. Use of a stringent dimerizer-regulated gene expression system for controlled BMP2 delivery. Mol Ther, 2006, 14: 684–691.
87. Wang X, Chen X, Yang Y. Spatiotemporal control of gene expression by a light-switchable transgene system. Nat Methods, 2012, 9: 266–269.
88. Vilaboa N, Boellmann F, Voellmy R. Gene switches for deliberate regulation of transgene expresiion: recent advances in system development and uses. J Genet Syndr Gene Ther, 2011, 2: 107.
89. Rome C, Couillaud F, Moonen CT. Spatial and temporal control of expression of therapeutic genes using heat shock protein promoters. Methods, 2005, 35: 188–198.
90. Vilaboa N, Fenna M, Munson J, Roberts SM, Voellmy R. Novel gene switches for targeted and timed expression of proteins of interest. Mol Ther, 2005, 12: 290–298.
91. Wilson CG, Martin-Saavedra FM, Vilaboa N, Franceschi RT. Advanced BMP gene therapies for temporal and spatial control of bone regeneration. J Dent Res, 2013, 92: 409–417.
92. Benazet JD, Zeller R. Vertebrate limb development: moving from classical morphogen gradients to an integrated 4-dimensional patterning system. Cold Spring Harb Perspect Biol, 2009, 1: a1339.
93. Suarez-Gonzalez D, Barnhart K, Migneco F, Flanagan C, Hollister SJ, Murphy WL. Controllable mineral coatings on PCL scaffolds as carriers for growth factor release. Biomaterials, 2012, 33: 713–721.
94. Tayalia P, Mooney DJ. Controlled growth factor delivery for tissue engineering. Adv Mater, 2009, 21: 3269–3285.
95. Li P, Bai Y, Yin G, et al. Synergistic and sequential effects of BMP-2, bFGF and VEGF on osteogenic differentiation of rat osteoblasts. J Bone Miner Metab, 2013, 2013: 1–9.
96. Vo TN, Kasper FK, Mikos AG. Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev, 2012, 64: 1292–1309.